Vioxx for migraine
Merck's COX-2 inhibitor Vioxx (rofecoxib) clears FDA for the acute treatment of migraines in adults March 26. Pfizer has submitted an sNDA for Bextra in the treatment of migraines; the application has an estimated user fee date in September...
You may also be interested in...
Merck's COX-2 inhibitor Vioxx is adding a migraine pain indication for the 25 mg and 50 mg doses
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.